3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Meningioma
1
Malignant Female Reproductive System Neoplasm
1
Hemangiosarcoma
1
Fallopian Tube Neoplasms
1
Ependymoma
1
Endometrial Neoplasms
1
Disease Progression
1
Colonic Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
36
Bevacizumab
25
Cyclophosphamide
23
Blood Specimen Collection
19
Nivolumab
17
Standard of Care
15
Carboplatin
15
Paclitaxel
14
atezolizumab
13
Gemcitabine
13
Exercise
13
Pemetrexed
11
Fluorouracil
11
Doxorubicin
11
Cisplatin
11
Cetuximab
10
Radiotherapy
9
Oxaliplatin
9
Magnetic Resonance Spectroscopy
9
Leucovorin
9
Docetaxel
9
130-nm albumin-bound paclitaxel
9
durvalumab
8
abemaciclib
8
Temozolomide
8
Surveys and Questionnaires
8
Rituximab
8
Prednisone
8
Biopsy
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
neratinib
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled